Skip to main content
Premium Trial:

Request an Annual Quote

Nuclea Biotechnologies Raises $6.4M to Support FDA Submission

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies today announced the closing of a financing round that raised $6.4 million.

The funding includes $4 million in new capital and the conversion of $2.4 million in outstanding notes into preferred stock, the Pittsfield, Mass.-based firm said.

In August GenomeWeb Daily News reported the company had closed on a Series B round that raised $4.7 million. The $6.4 million reported today includes the earlier amount, a company spokesman said.

The funding will be used to support regulatory approval of its fatty acid synthase assay, including clinical trials, as well as facility upgrades, new hires, and general operations. Nuclea CEO Patrick Muraca said in August that the company planned to submit its fatty acid synthase assay for approval from the US Food and Drug Administration by the end of September.

It is unclear whether the company has yet made its submission.

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.